International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update

In the 10 years since our previous International Union of Basic and Clinical Pharmacology report on the nomenclature and classification of adenosine receptors, no developments have led to major changes in the recommendations. However, there have been so many other developments that an update is needed. The fact that the structure of one of the adenosine receptors has recently been solved has already led to new ways of in silico screening of ligands. The evidence that adenosine receptors can form homo- and heteromultimers has accumulated, but the functional significance of such complexes remains unclear. The availability of mice with genetic modification of all the adenosine receptors has led to a clarification of the functional roles of adenosine, and to excellent means to study the specificity of drugs. There are also interesting associations between disease and structural variants in one or more of the adenosine receptors. Several new selective agonists and antagonists have become available. They provide improved possibilities for receptor classification. There are also developments hinting at the usefulness of allosteric modulators. Many drugs targeting adenosine receptors are in clinical trials, but the established therapeutic use is still very limited.

[1]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[2]  Xiaowei Jin,et al.  Inosine Binds to A 3 Adenosine Receptors and Stimulates Mast Cell Degranulation , 2013 .

[3]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[4]  Kenneth A Jacobson,et al.  Recent developments in adenosine receptor ligands and their potential as novel drugs. , 2011, Biochimica et biophysica acta.

[5]  K. Varani,et al.  A₃ receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt/nuclear factor-κB pathway. , 2011, American journal of respiratory and critical care medicine.

[6]  K. Varani,et al.  Adenosine receptors in health and disease. , 2011, Advances in pharmacology.

[7]  C. Freitag,et al.  Adenosine A(2A) receptor gene: evidence for association of risk variants with panic disorder and anxious personality. , 2010, Journal of psychiatric research.

[8]  P. White,et al.  Delineating the Mode of Action of Adenosine A1 Receptor Allosteric Modulators , 2010, Molecular Pharmacology.

[9]  K. Jacobson,et al.  Novel Alexa Fluor-488 labeled antagonist of the A(2A) adenosine receptor: Application to a fluorescence polarization-based receptor binding assay. , 2010, Biochemical pharmacology.

[10]  B. Fredholm,et al.  Adenosine A1 receptors (A1Rs) play a critical role in osteoclast formation and function , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  K. Jacobson,et al.  Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. , 2010, Ophthalmology.

[12]  Wei Liu,et al.  Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture , 2010, Nature Neuroscience.

[13]  B. Fredholm,et al.  Adenosine A1 receptors and vascular reactivity , 2010, Acta physiologica.

[14]  K. Varani,et al.  Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes , 2010, British journal of pharmacology.

[15]  Brian K. Shoichet,et al.  Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.

[16]  Judy Lin,et al.  Hybrid ortho/allosteric ligands for the adenosine A(1) receptor. , 2010, Journal of medicinal chemistry.

[17]  S. Chandra,et al.  Synthesis and biological evaluation of 99mTc-DHPM complex: a potential new radiopharmaceutical for lung imaging studies , 2010 .

[18]  Sergio Paredes,et al.  Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists. , 2010, Bioorganic & medicinal chemistry letters.

[19]  B. Fredholm,et al.  Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice. , 2010, Arthritis and rheumatism.

[20]  Ruben Abagyan,et al.  Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.

[21]  K. Jacobson,et al.  Adenosine A3 Receptors in Muscle Protection , 2010 .

[22]  Thea Mulder-Krieger,et al.  The endocannabinoid 2-arachidonylglycerol is a negative allosteric modulator of the human A3 adenosine receptor. , 2010, Biochemical pharmacology.

[23]  Ruben Abagyan,et al.  Structure-Based Discovery of Novel Chemotypes for Adenosine A 2 A Receptor Antagonists , 2010 .

[24]  J. Giraldo,et al.  The asymmetric/symmetric activation of GPCR dimers as a possible mechanistic rationale for multiple signalling pathways. , 2010, Trends in pharmacological sciences.

[25]  K. Klotz,et al.  Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5'-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A3 receptor. , 2009, Journal of Medicinal Chemistry.

[26]  A. Pinna Novel investigational adenosine A2A receptor antagonists for Parkinson's disease , 2009, Expert opinion on investigational drugs.

[27]  Antagonists of the Human A2A Receptor. Part 5. Highly Bio-Available Pyrimidine-4-carboxamides. , 2009 .

[28]  A. Iskandrian,et al.  Regadenoson: a new myocardial stress agent. , 2009, Journal of the American College of Cardiology.

[29]  Michael R. Elliott,et al.  Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance , 2009, Nature.

[30]  J. Linden,et al.  Adenosine A2B receptors are highly expressed on murine type II alveolar epithelial cells. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[31]  Marta Filizola,et al.  Modern homology modeling of G-protein coupled receptors: which structural template to use? , 2009, Journal of medicinal chemistry.

[32]  H. Kaneko,et al.  A highly conserved tryptophan residue in the fourth transmembrane domain of the A1 adenosine receptor is essential for ligand binding but not receptor homodimerization , 2009, Journal of neurochemistry.

[33]  K. Fuxe,et al.  Interactions between Calmodulin, Adenosine A2A, and Dopamine D2 Receptors* , 2009, The Journal of Biological Chemistry.

[34]  Arthur Christopoulos,et al.  Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. , 2009, Journal of medicinal chemistry.

[35]  J. F. Chen,et al.  Adenosine, adenosine A 2A antagonists, and Parkinson's disease. , 2009, Parkinsonism & related disorders.

[36]  Masahiko Watanabe,et al.  Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher‐order oligomers in living cells , 2009, Journal of neurochemistry.

[37]  S. Lévy,et al.  Head-up tilt induced syncope and adenosine A2A receptor gene polymorphism. , 2009, European heart journal.

[38]  Charles L. Brooks,et al.  Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008 , 2009, Nature Reviews Drug Discovery.

[39]  Dov Barak,et al.  Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. , 2009, Journal of medicinal chemistry.

[40]  Thomas Borrmann,et al.  1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. , 2009, Journal of medicinal chemistry.

[41]  K. Jacobson,et al.  Novel 2- and 4-substituted 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric modulators of the A3 adenosine receptor. , 2009, Journal of medicinal chemistry.

[42]  Bruno Antonny,et al.  The apparent cooperativity of some GPCRs does not necessarily imply dimerization. , 2009, Trends in pharmacological sciences.

[43]  B. Fredholm,et al.  Physiological roles of A1 and A2A adenosine receptors in regulating heart rate, body temperature, and locomotion as revealed using knockout mice and caffeine. , 2009, American journal of physiology. Heart and circulatory physiology.

[44]  Dharini van der Hoeven,et al.  Characterization of the A2B Adenosine Receptor from Mouse, Rabbit, and Dog , 2009, Journal of Pharmacology and Experimental Therapeutics.

[45]  R. Tsien,et al.  The Dynamic Control of Kiss-And-Run and Vesicular Reuse Probed with Single Nanoparticles , 2009, Science.

[46]  Michel Bouvier,et al.  Building a new conceptual framework for receptor heteromers. , 2009, Nature chemical biology.

[47]  K. Min,et al.  Adenosine deaminase and adenosine receptor polymorphisms in aspirin-intolerant asthma. , 2009, Respiratory medicine.

[48]  B. Fredholm,et al.  Mice heterozygous for both A1 and A(2A) adenosine receptor genes show similarities to mice given long-term caffeine. , 2009, Journal of applied physiology.

[49]  Thea Mulder-Krieger,et al.  A series of 2,4-disubstituted quinolines as a new class of allosteric enhancers of the adenosine A3 receptor. , 2009, Journal of medicinal chemistry.

[50]  A. Knight,et al.  Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. , 2009, Journal of medicinal chemistry.

[51]  P. Fishman,et al.  The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease. , 2009, Cellular immunology.

[52]  K. Jacobson Introduction to adenosine receptors as therapeutic targets. , 2009, Handbook of experimental pharmacology.

[53]  Arthur Christopoulos,et al.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders , 2009, Nature Reviews Drug Discovery.

[54]  B. Fredholm,et al.  Perinatal Caffeine, Acting on Maternal Adenosine A1 Receptors, Causes Long-Lasting Behavioral Changes in Mouse Offspring , 2008, PloS one.

[55]  B. Fredholm,et al.  Adenosine in the tuberomammillary nucleus inhibits the histaminergic system via A1 receptors and promotes non-rapid eye movement sleep , 2008, Proceedings of the National Academy of Sciences.

[56]  Adriaan P IJzerman,et al.  Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models , 2009, BMC pharmacology.

[57]  Pierre-Alexandre Vidi,et al.  Adenosine A2A receptors assemble into higher‐order oligomers at the plasma membrane , 2008, FEBS letters.

[58]  F. Ciruela,et al.  Plasma membrane diffusion of G protein-coupled receptor oligomers. , 2008, Biochimica et biophysica acta.

[59]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[60]  E. Elzein,et al.  A1 adenosine receptor agonists and their potential therapeutic applications , 2008 .

[61]  R. Hauser,et al.  Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations , 2008, Movement disorders : official journal of the Movement Disorder Society.

[62]  B. Fredholm,et al.  Adenosine A1 receptors regulate lipolysis and lipogenesis in mouse adipose tissue-interactions with insulin. , 2008, European journal of pharmacology.

[63]  J. Linden,et al.  Adenosine A2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation. , 2008, American journal of physiology. Heart and circulatory physiology.

[64]  F. Ciruela,et al.  Detection of Heteromers Formed by Cannabinoid CB1, Dopamine D2, and Adenosine A2A G-Protein-Coupled Receptors by Combining Bimolecular Fluorescence Complementation and Bioluminescence Energy Transfer , 2008, TheScientificWorldJournal.

[65]  C. O'connor,et al.  The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. , 2008, Journal of cardiac failure.

[66]  J. P. Petzer,et al.  Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. , 2008, Bioorganic & medicinal chemistry.

[67]  F. Ciruela,et al.  Detection of higher‐order G protein‐coupled receptor oligomers by a combined BRET–BiFC technique , 2008, FEBS letters.

[68]  Pierre-Alexandre Vidi,et al.  Ligand-Dependent Oligomerization of Dopamine D2 and Adenosine A2A Receptors in Living Neuronal Cells , 2008, Molecular Pharmacology.

[69]  K. Varani,et al.  Synthesis and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[N-(substituted) piperazin-1-yl]thiophenes as potent allosteric enhancers of the A1 adenosine receptor. , 2008, Journal of medicinal chemistry.

[70]  Yoko Shibata,et al.  Co-evolving stability and conformational homogeneity of the human adenosine A2a receptor , 2008, Proceedings of the National Academy of Sciences.

[71]  Anna Maria Bianucci,et al.  N6-1,3-diphenylurea derivatives of 2-phenyl-9-benzyladenines and 8-azaadenines: synthesis and biological evaluation as allosteric modulators of A2A adenosine receptors. , 2008, European journal of medicinal chemistry.

[72]  Gemma Navarro,et al.  Detection of heteromerization of more than two proteins by sequential BRET-FRET , 2008, Nature Methods.

[73]  B. Fredholm,et al.  Adenosine induces airway hyperresponsiveness through activation of A3 receptors on mast cells. , 2008, The Journal of allergy and clinical immunology.

[74]  I. Bruce,et al.  Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX , 2008, Rheumatology.

[75]  M. Stacy,et al.  A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease , 2008, Neurology.

[76]  C. Ledent,et al.  Up-regulation of A 2B adenosine receptor in A 2A adenosine receptor knockout mouse coronary artery. , 2008, Journal of molecular and cellular cardiology.

[77]  K. Jacobson,et al.  Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. , 2008, Bioorganic & medicinal chemistry letters.

[78]  J. Tsien,et al.  A Critical Role of the Adenosine A2A Receptor in Extrastriatal Neurons in Modulating Psychomotor Activity as Revealed by Opposite Phenotypes of Striatum and Forebrain A2A Receptor Knock-Outs , 2008, The Journal of Neuroscience.

[79]  David A. Lustig,et al.  Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. , 2008, Journal of medicinal chemistry.

[80]  P. Tuite,et al.  Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005) , 2008, Annals of neurology.

[81]  J. Badner,et al.  Association between ADORA2A and DRD2 Polymorphisms and Caffeine-Induced Anxiety , 2008, Neuropsychopharmacology.

[82]  Krzysztof Palczewski,et al.  Efficient Coupling of Transducin to Monomeric Rhodopsin in a Phospholipid Bilayer* , 2008, Journal of Biological Chemistry.

[83]  I. Biaggioni,et al.  Effect of A2B Adenosine Receptor Gene Ablation on Adenosine-Dependent Regulation of Proinflammatory Cytokines , 2008, Journal of Pharmacology and Experimental Therapeutics.

[84]  M. Koupenova,et al.  The A2b adenosine receptor protects against vascular injury , 2008, Proceedings of the National Academy of Sciences.

[85]  G. Gross,et al.  The A3 Adenosine Receptor Agonist CP-532,903 [N6-(2,5-Dichlorobenzyl)-3′-aminoadenosine-5′-N-methylcarboxamide] Protects against Myocardial Ischemia/Reperfusion Injury via the Sarcolemmal ATP-Sensitive Potassium Channel , 2008, Journal of Pharmacology and Experimental Therapeutics.

[86]  B. Fredholm,et al.  A1 receptor deficiency causes increased insulin and glucagon secretion in mice. , 2007, Biochemical pharmacology.

[87]  B. Fredholm,et al.  1,3,7-Trimethylxanthine (Caffeine) May Exacerbate Acute Inflammatory Liver Injury by Weakening the Physiological Immunosuppressive Mechanism1 , 2007, The Journal of Immunology.

[88]  F. Pedata,et al.  Adenosine A2A receptors and brain injury: Broad spectrum of neuroprotection, multifaceted actions and “fine tuning” modulation , 2007, Progress in Neurobiology.

[89]  B. Fredholm,et al.  Adenosine dysfunction in astrogliosis: cause for seizure generation? , 2007, Neuron glia biology.

[90]  K. Ardlie,et al.  Polymorphisms in Adenosine Receptor Genes are Associated with Infarct Size in Patients with Ischemic Cardiomyopathy , 2007, Clinical pharmacology and therapy.

[91]  J. Downey,et al.  Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. , 2007, Journal of molecular and cellular cardiology.

[92]  F. Popescu,et al.  A review of antisense therapeutic interventions for molecular biological targets in asthma , 2007, Biologics : targets & therapy.

[93]  B. Hocher,et al.  The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure , 2007, British journal of pharmacology.

[94]  Joseph Shiloach,et al.  Dimerization of the class A G protein-coupled neurotensin receptor NTS1 alters G protein interaction , 2007, Proceedings of the National Academy of Sciences.

[95]  K. Ley,et al.  Therapeutic Anti-Inflammatory Effects of Myeloid Cell Adenosine Receptor A2a Stimulation in Lipopolysaccharide-Induced Lung Injury1 , 2007, The Journal of Immunology.

[96]  Qingming Luo,et al.  Regulated ATP release from astrocytes through lysosome exocytosis , 2007, Nature Cell Biology.

[97]  X. Hua,et al.  Involvement of A1 adenosine receptors and neural pathways in adenosine-induced bronchoconstriction in mice. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[98]  Carolyn M. McClaskey,et al.  A1 adenosine receptors play an essential role in protecting the embryo against hypoxia , 2007, Proceedings of the National Academy of Sciences.

[99]  Geoffrey D. Clarke,et al.  Reduced response to the formalin test and lowered spinal NMDA glutamate receptor binding in adenosine A2A receptor knockout mice , 2007, PAIN.

[100]  B. Fredholm,et al.  Eliminating the antilipolytic adenosine A1 receptor does not lead to compensatory changes in the antilipolytic actions of PGE2 and nicotinic acid , 2007, Acta physiologica.

[101]  B. Fredholm,et al.  Sex differences in mouse heart rate and body temperature and in their regulation by adenosine A1 receptors , 2007, Acta physiologica.

[102]  M. Loza,et al.  Discovery and characterization of 4'-(2-furyl)-N-pyridin-3-yl-4,5'-bipyrimidin-2'-amine (LAS38096), a potent, selective, and efficacious A2B adenosine receptor antagonist. , 2007, Journal of medicinal chemistry.

[103]  Richard N. Zare,et al.  A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein , 2007, Proceedings of the National Academy of Sciences.

[104]  H. Landolt,et al.  A Genetic Variation in the Adenosine A2A Receptor Gene (ADORA2A) Contributes to Individual Sensitivity to Caffeine Effects on Sleep , 2007, Clinical pharmacology and therapeutics.

[105]  C. Ledent,et al.  Cardioprotection by Ecto-5′-Nucleotidase (CD73) and A2B Adenosine Receptors , 2007, Circulation.

[106]  F. Ciruela,et al.  Striatal Adenosine A2A and Cannabinoid CB1 Receptors Form Functional Heteromeric Complexes that Mediate the Motor Effects of Cannabinoids , 2007, Neuropsychopharmacology.

[107]  Michel Bouvier,et al.  International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the Recognition and Nomenclature of G Protein-Coupled Receptor Heteromultimers , 2007, Pharmacological Reviews.

[108]  K. Klotz,et al.  [3H]HEMADO--a novel tritiated agonist selective for the human adenosine A3 receptor. , 2007, European journal of pharmacology.

[109]  K. Varani,et al.  Synthesis and biological evaluation of novel 1-deoxy-1-[6-[((hetero)arylcarbonyl)hydrazino]- 9H-purin-9-yl]-N-ethyl-beta-D-ribofuranuronamide derivatives as useful templates for the development of A2B adenosine receptor agonists. , 2007, Journal of medicinal chemistry.

[110]  X. Hua,et al.  Enhanced mast cell activation in mice deficient in the A2b adenosine receptor , 2007, The Journal of Experimental Medicine.

[111]  X. Hua,et al.  Enhanced mast cell activation in mice deficient in the A2b adenosine receptor , 2007, The Journal of experimental medicine.

[112]  A. IJzerman,et al.  2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. , 2007, Journal of medicinal chemistry.

[113]  P. Baraldi,et al.  Allosteric enhancers for A1 adenosine receptor. , 2007, Mini reviews in medicinal chemistry.

[114]  H. Nakata,et al.  Functions of heteromeric association between adenosine and P2Y receptors , 2007, Journal of Molecular Neuroscience.

[115]  C. Müller,et al.  Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders. , 2007, Recent patents on CNS drug discovery.

[116]  H. Nakata,et al.  Regulation of pharmacology by hetero-oligomerization between A1 adenosine receptor and P2Y2 receptor. , 2006, Biochemical and biophysical research communications.

[117]  Linda Yip,et al.  ATP Release Guides Neutrophil Chemotaxis via P2Y2 and A3 Receptors , 2006, Science.

[118]  G. Gross,et al.  Cl-IB-MECA [2-Chloro-N6-(3-iodobenzyl)adenosine-5′-N-methylcarboxamide] Reduces Ischemia/Reperfusion Injury in Mice by Activating the A Adenosine Receptor , 2006, Journal of Pharmacology and Experimental Therapeutics.

[119]  B. Ransom,et al.  Functional connexin “hemichannels”: A critical appraisal , 2006, Glia.

[120]  Yaqin Xu,et al.  Myocardial Infarct–Sparing Effect of Adenosine A2A Receptor Activation Is due to Its Action on CD4+ T Lymphocytes , 2006, Circulation.

[121]  Xiaowei Jin,et al.  Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. , 2006, Journal of medicinal chemistry.

[122]  Liqun Yu,et al.  Adenosine A2A Receptors in Bone Marrow-Derived Cells But Not in Forebrain Neurons Are Important Contributors to 3-Nitropropionic Acid-Induced Striatal Damage as Revealed by Cell-Type-Selective Inactivation , 2006, The Journal of Neuroscience.

[123]  P. MacDonald,et al.  Release of small transmitters through kiss-and-run fusion pores in rat pancreatic beta cells. , 2006, Cell metabolism.

[124]  W. Oyen,et al.  Caffeine prevents protection in two human models of ischemic preconditioning. , 2006, Journal of the American College of Cardiology.

[125]  K. Klotz,et al.  Improving Potency, Selectivity, and Water Solubility of Adenosine A1 Receptor Antagonists: Xanthines Modified at Position 3 and Related Pyrimido[1,2,3‐cd]purinediones , 2006, ChemMedChem.

[126]  Seiko F. Okada,et al.  Physiological Regulation of ATP Release at the Apical Surface of Human Airway Epithelia*♦ , 2006, Journal of Biological Chemistry.

[127]  Stephen A Baldwin,et al.  Nucleoside transporters: from scavengers to novel therapeutic targets. , 2006, Trends in pharmacological sciences.

[128]  C. Müller,et al.  Characterization of human and rodent native and recombinant adenosine A2B receptors by radioligand binding studies , 2006, Purinergic Signalling.

[129]  M. Koupenova,et al.  The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. , 2006, The Journal of clinical investigation.

[130]  B. Fredholm,et al.  Adenosine A1 receptors are crucial in keeping an epileptic focus localized , 2006, Experimental Neurology.

[131]  Johannes Brussee,et al.  Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor. , 2006, Journal of medicinal chemistry.

[132]  Xiaowei Jin,et al.  Norbornyllactone-substituted xanthines as adenosine A(1) receptor antagonists. , 2006, Bioorganic & medicinal chemistry.

[133]  A. Tucker,et al.  The allosteric enhancer PD81,723 increases chimaeric A1/A2A adenosine receptor coupling with Gs. , 2006, The Biochemical journal.

[134]  B. Fredholm,et al.  Effect of modulating cardiac A1 adenosine receptor expression on protection with ischemic preconditioning. , 2006, American journal of physiology. Heart and circulatory physiology.

[135]  G. Nikolakopoulos,et al.  2-Aminothiophene-3-carboxylates and carboxamides as adenosine A1 receptor allosteric enhancers. , 2006, Bioorganic & medicinal chemistry.

[136]  P. Kochanek,et al.  Adenosine A1 Receptor Knockout Mice Develop Lethal Status Epilepticus after Experimental Traumatic Brain Injury , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[137]  A. IJzerman,et al.  Allosteric modulation, thermodynamics and binding to wild‐type and mutant (T277A) adenosine A1 receptors of LUF5831, a novel nonadenosine‐like agonist , 2006, British journal of pharmacology.

[138]  K. Varani,et al.  Synthesis and biological characterization of [3H] (2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)-(4-chlorophenyl)-methanone, the first radiolabelled adenosine A1 allosteric enhancer. , 2006, Bioorganic & medicinal chemistry letters.

[139]  K. Jacobson,et al.  Adenosine receptors as therapeutic targets , 2006, Nature Reviews Drug Discovery.

[140]  Geoffrey Burnstock,et al.  Historical review: ATP as a neurotransmitter. , 2006, Trends in pharmacological sciences.

[141]  Graeme Milligan,et al.  Presynaptic Control of Striatal Glutamatergic Neurotransmission by Adenosine A1–A2A Receptor Heteromers , 2006, The Journal of Neuroscience.

[142]  T. Schwartz,et al.  Ago-Allosteric Modulation and Other Types of Allostery in Dimeric 7TM Receptors , 2006, Journal of receptor and signal transduction research.

[143]  P. Sexton,et al.  Effects of urea pretreatment on the binding properties of adenosine A1 receptors , 2005, British journal of pharmacology.

[144]  J. Linden,et al.  Lipopolysaccharide rapidly modifies adenosine receptor transcripts in murine and human macrophages: role of NF-kappaB in A(2A) adenosine receptor induction. , 2005, The Biochemical journal.

[145]  H. Landolt,et al.  A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[146]  Giovanni Piersanti,et al.  2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. , 2005, Journal of medicinal chemistry.

[147]  S. Doggrell BG-9928 (Biogen Idec). , 2005, Current opinion in investigational drugs.

[148]  M. Chordia,et al.  6-aryl-8H-indeno[1,2-d]thiazol-2-ylamines: A1 adenosine receptor agonist allosteric enhancers having improved potency. , 2005, Journal of medicinal chemistry.

[149]  B. Fredholm,et al.  Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine , 2005, Nature Neuroscience.

[150]  M. le Maire,et al.  Monomeric G-protein-coupled receptor as a functional unit. , 2005, Biochemistry.

[151]  Kenneth A Jacobson,et al.  Allosteric modulation of the adenosine family of receptors. , 2005, Mini reviews in medicinal chemistry.

[152]  J. Linden,et al.  A Crucial Role for Forebrain Adenosine A2A Receptors in Amphetamine Sensitization , 2005, Neuropsychopharmacology.

[153]  S. Robson,et al.  Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. , 2005, Seminars in thrombosis and hemostasis.

[154]  A. IJzerman,et al.  A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor. , 2005, Journal of medicinal chemistry.

[155]  A. IJzerman,et al.  Synthesis and biological evaluation of 2-aminothiazoles and their amide derivatives on human adenosine receptors. Lack of effect of 2-aminothiazoles as allosteric enhancers. , 2005, Bioorganic & medicinal chemistry.

[156]  R. Leurs,et al.  A "locked-on," constitutively active mutant of the adenosine A1 receptor. , 2005, European journal of pharmacology.

[157]  J. Schnermann,et al.  Role of A1 adenosine receptors in regulation of vascular tone. , 2005, American journal of physiology. Heart and circulatory physiology.

[158]  B. Fredholm,et al.  Increased nociceptive response in mice lacking the adenosine A1 receptor , 2005, Pain.

[159]  K. Fuxe,et al.  Adenosine A2A Receptor and Dopamine D3 Receptor Interactions: Evidence of Functional A2A/D3 Heteromeric Complexes , 2005, Molecular Pharmacology.

[160]  Courtney M. Lappas,et al.  A2A Adenosine Receptor Induction Inhibits IFN-γ Production in Murine CD4+ T Cells1 , 2005, The Journal of Immunology.

[161]  Matthew R. Jones,et al.  Animal models for the study of adenosine receptor function , 2005, Journal of cellular physiology.

[162]  B. Fredholm,et al.  Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. , 2005, Annual review of pharmacology and toxicology.

[163]  Courtney M. Lappas,et al.  A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. , 2005, Journal of immunology.

[164]  C. Müller,et al.  Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats , 2005, Psychopharmacology.

[165]  S. Colgan,et al.  Crucial Role for Ecto-5′-Nucleotidase (CD73) in Vascular Leakage during Hypoxia , 2004, The Journal of experimental medicine.

[166]  K. Ley,et al.  Targeted Disruption of cd73/Ecto-5′-Nucleotidase Alters Thromboregulation and Augments Vascular Inflammatory Response , 2004, Circulation research.

[167]  B. Fredholm,et al.  Adenosine A1 receptors are necessary for protection of the murine heart by remote, delayed adaptation to ischaemia , 2004 .

[168]  A. IJzerman,et al.  New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. , 2004, Journal of medicinal chemistry.

[169]  Susan E Hodge,et al.  Evidence for Genetic Linkage Between a Polymorphism in the Adenosine 2A Receptor and Panic Disorder , 2004, Neuropsychopharmacology.

[170]  K. Varani,et al.  Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. , 2004, Journal of medicinal chemistry.

[171]  C. Müller,et al.  Antinociceptive Effects of Novel A2B Adenosine Receptor Antagonists , 2004, Journal of Pharmacology and Experimental Therapeutics.

[172]  K. Fuxe,et al.  Homodimerization of adenosine A2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer , 2003, Journal of neurochemistry.

[173]  K. Klotz,et al.  Comparison of A1 adenosine receptors in brain from different species by radioligand binding and photoaffinity labelling , 1991, Naunyn-Schmiedeberg's Archives of Pharmacology.

[174]  J. Ramachandran,et al.  Structure and Function of G Protein Coupled Receptors , 1990, Pharmaceutical Research.

[175]  Hiroshi Kase,et al.  Industry forum: Progress in pursuit of therapeutic A2A antagonists , 2003, Neurology.

[176]  B. Fredholm,et al.  Sleep and its homeostatic regulation in mice lacking the adenosine A1 receptor , 2003, Journal of Sleep Research.

[177]  Francesca Fanelli,et al.  Adenosine A2A-Dopamine D2 Receptor-Receptor Heteromerization , 2003, Journal of Biological Chemistry.

[178]  C. Müller,et al.  Adenosine receptor agonists: from basic medicinal chemistry to clinical development , 2003, Expert opinion on emerging drugs.

[179]  T Kendall Harden,et al.  Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. , 2003, Molecular pharmacology.

[180]  J. Fozard,et al.  Antagonist pharmacology of adenosine A2B receptors from rat, guinea pig and dog. , 2003, European journal of pharmacology.

[181]  R. J. Hill,et al.  Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. , 2003, American journal of physiology. Heart and circulatory physiology.

[182]  C. Saper,et al.  Focal Deletion of the Adenosine A1 Receptor in Adult Mice Using an Adeno-Associated Viral Vector , 2003, The Journal of Neuroscience.

[183]  H. Nakata,et al.  Oligomerization of adenosine A2A and dopamine D2 receptors in living cells. , 2003, Biochemical and biophysical research communications.

[184]  P. Sand,et al.  Association Between A2a Receptor Gene Polymorphisms and Caffeine-Induced Anxiety , 2003, Neuropsychopharmacology.

[185]  A. Ohta,et al.  Analysis of A2a receptor-deficient mice reveals no significant compensatory increases in the expression of A2b, A1, and A3 adenosine receptors in lymphoid organs. , 2003, Biochemical pharmacology.

[186]  J. Eisenach,et al.  Allosteric Adenosine Receptor Modulation Reduces Hypersensitivity Following Peripheral Inflammation by a Central Mechanism , 2003, Journal of Pharmacology and Experimental Therapeutics.

[187]  Kenneth A Jacobson,et al.  Identification of essential residues involved in the allosteric modulation of the human A(3) adenosine receptor. , 2003, Molecular pharmacology.

[188]  R. Boucher,et al.  Ecto 5′-Nucleotidase and Nonspecific Alkaline Phosphatase , 2003, The Journal of Biological Chemistry.

[189]  Adriaan P IJzerman,et al.  N6-cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor. , 2003, Journal of medicinal chemistry.

[190]  K. Jacobson,et al.  Differential allosteric modulation by amiloride analogues of agonist and antagonist binding at A(1) and A(3) adenosine receptors. , 2003, Biochemical Pharmacology.

[191]  K. Jacobson,et al.  2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors. , 2003, Bioorganic & medicinal chemistry.

[192]  M. Maj,et al.  Formalin-induced pain and μ-opioid receptor density in brain and spinal cord are modulated by A1 and A2 a adenosine agonists in mice , 2002, Brain Research.

[193]  Y. Kuroda,et al.  Hetero‐oligomerization of adenosine A1 receptors with P2Y1 receptors in rat brains , 2002, FEBS letters.

[194]  B. Fredholm,et al.  Decreased inflammatory pain due to reduced carrageenan-induced inflammation in mice lacking adenosine A3 receptors , 2002, Neuroscience.

[195]  Dirk Bier,et al.  Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. , 2002, Journal of medicinal chemistry.

[196]  B. Fredholm,et al.  Modulation of Hippocampal Glutamatergic Transmission by ATP Is Dependent on Adenosine A1 Receptors , 2002, Journal of Pharmacology and Experimental Therapeutics.

[197]  L. Agnati,et al.  Interactions among adenosine deaminase, adenosine A1 receptors and dopamine D1 receptors in stably cotransfected fibroblast cells and neurons , 2002, Neuroscience.

[198]  Kenneth A Jacobson,et al.  Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists. , 2002, Journal of medicinal chemistry.

[199]  Adriaan P IJzerman,et al.  Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives. , 2002, Molecular pharmacology.

[200]  K. Klotz,et al.  N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. , 2002, Journal of medicinal chemistry.

[201]  H. Yee,et al.  Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. , 2002, The American journal of pathology.

[202]  J. Shimada,et al.  KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist. , 2002, European journal of pharmacology.

[203]  K. Jacobson,et al.  Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. , 2002, Journal of medicinal chemistry.

[204]  Michele Zoli,et al.  Coaggregation, Cointernalization, and Codesensitization of Adenosine A2A Receptors and Dopamine D2Receptors* , 2002, The Journal of Biological Chemistry.

[205]  B. Fowler,et al.  Neonatal hepatic steatosis by disruption of the adenosine kinase gene , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[206]  C. Müller,et al.  1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists. , 2002, Journal of medicinal chemistry.

[207]  Christa E. Müller,et al.  [3H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1h-imidazo[2,1-i]-purin-5- one ([3H]PSB-11), a novel high-affinity antagonist radioligand for human A3 adenosine receptors , 2002 .

[208]  C. Ledent,et al.  Cardiac effects of adenosine in A(2A) receptor knockout hearts: uncovering A(2B) receptors. , 2002, American journal of physiology. Heart and circulatory physiology.

[209]  C. Müller,et al.  [(3)H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]-purin-5-one ([(3)H]PSB-11), a novel high-affinity antagonist radioligand for human A(3) adenosine receptors. , 2002, Bioorganic & medicinal chemistry letters.

[210]  A. Ohta,et al.  Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage , 2001, Nature.

[211]  B. Fredholm,et al.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.

[212]  K. Jacobson,et al.  Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. , 2001, Molecular pharmacology.

[213]  B. Fredholm,et al.  Abolished tubuloglomerular feedback and increased plasma renin in adenosine A1 receptor-deficient mice. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[214]  Tianxin Yang,et al.  Mediation of tubuloglomerular feedback by adenosine: Evidence from mice lacking adenosine 1 receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[215]  B. Fredholm,et al.  Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[216]  H. Nakata,et al.  Heteromeric association creates a P2Y-like adenosine receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[217]  M. Schwarzschild,et al.  Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease , 2001, The Journal of Neuroscience.

[218]  W. Bao,et al.  Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. , 2001, Journal of molecular and cellular cardiology.

[219]  M. Low,et al.  The role of the D2 dopamine receptor (D2R) in A2A adenosine receptor (A2AR)-mediated behavioral and cellular responses as revealed by A2A and D2 receptor knockout mice , 2001 .

[220]  B. Fredholm,et al.  Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. , 2001, Biochemical pharmacology.

[221]  A. IJzerman,et al.  Differential effects of the allosteric enhancer (2-amino-4,5-dimethyl-trienyl)[3-trifluoromethyl) phenyl]methanone (PD81,723) on agonist and antagonist binding and function at the human wild-type and a mutant (T277A) adenosine A1 receptor. , 2001, Biochemical pharmacology.

[222]  J. F. Chen,et al.  The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[223]  R. Boucher,et al.  Constitutive Release of ATP and Evidence for Major Contribution of Ecto-nucleotide Pyrophosphatase and Nucleoside Diphosphokinase to Extracellular Nucleotide Concentrations* , 2000, The Journal of Biological Chemistry.

[224]  A. IJzerman,et al.  Allosteric modulation of A(2A) adenosine receptors by amiloride analogues and sodium ions. , 2000, Biochemical pharmacology.

[225]  I. Lampronti,et al.  Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of A1-adenosine receptor. , 2000, Bioorganic & medicinal chemistry letters.

[226]  B. Fredholm,et al.  Human adenosine A(1), A(2A), A(2B), and A(3) receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. , 2000, Molecular pharmacology.

[227]  E I Canela,et al.  Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[228]  C. Müller,et al.  Binding of [3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes--a new, selective antagonist radioligand for A(2A) adenosine receptors. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[229]  A. IJzerman,et al.  Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A(3) receptor. , 2000, Journal of medicinal chemistry.

[230]  A. IJzerman,et al.  Elucidation of structure–activity relationships of 2‐amino‐3‐benzoylthiophenes: Study of their allosteric enhancing vs. antagonistic activity on adenosine A1 receptors , 2000 .

[231]  Marc Parmentier,et al.  The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A2A receptors , 2000, British journal of pharmacology.

[232]  D. Standaert,et al.  Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A2A adenosine receptors , 2000, Neuroscience.

[233]  K. Jacobson,et al.  Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. , 2000, Journal of medicinal chemistry.

[234]  Beverly H. Koller,et al.  Disruption of the A3 Adenosine Receptor Gene in Mice and Its Effect on Stimulated Inflammatory Cells* , 2000, The Journal of Biological Chemistry.

[235]  M. Jacobson,et al.  Adenosine and inosine increase cutaneous vasopermeability by activating A(3) receptors on mast cells. , 2000, The Journal of clinical investigation.

[236]  K. Klotz,et al.  Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists. , 2000, Journal of medicinal chemistry.

[237]  C. Müller A2A adenosine receptor antagonists - future drugs for Parkinson's disease? , 2000 .

[238]  C. E. Műller Adenosine receptor ligands-recent developments part I. Agonists. , 2000, Current medicinal chemistry.

[239]  P. Svenningsson,et al.  Distribution, biochemistry and function of striatal adenosine A2A receptors , 1999, Progress in Neurobiology.

[240]  M. Moskowitz,et al.  A2A Adenosine Receptor Deficiency Attenuates Brain Injury Induced by Transient Focal Ischemia in Mice , 1999, The Journal of Neuroscience.

[241]  Patricia D. Christie,et al.  Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation , 1999, Nature Medicine.

[242]  A. IJzerman,et al.  Allosteric modulation of the adenosine A(1) receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding. , 1999, Journal of medicinal chemistry.

[243]  K. Jacobson,et al.  Acyl‐hydrazide derivatives of a xanthine carboxylic congener (XCC) as selective antagonists at human A2B adenosine receptors , 1999 .

[244]  K. Jacobson,et al.  1,3‐dialkylxanthine derivatives having high potency as antagonists at human A2B adenosine receptors , 1999, Drug development research.

[245]  B. Fredholm,et al.  Signaling via A2A adenosine receptor in four PC12 cell clones , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[246]  A. IJzerman,et al.  A novel class of adenosine A3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives. , 1998, Journal of medicinal chemistry.

[247]  C. Martini,et al.  2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies. , 1998, Journal of medicinal chemistry.

[248]  M. Blackburn,et al.  Adenosine Deaminase-deficient Mice Generated Using a Two-stage Genetic Engineering Strategy Exhibit a Combined Immunodeficiency* , 1998, The Journal of Biological Chemistry.

[249]  K. Fuxe,et al.  Adenosine A1 Receptor-mediated Modulation of Dopamine D1 Receptors in Stably Cotransfected Fibroblast Cells* , 1998, The Journal of Biological Chemistry.

[250]  M. Nöthen,et al.  Systematic mutation screening and association study of the A1 and A2a adenosine receptor genes in panic disorder suggest a contribution of the A2a gene to the development of disease , 1998, Molecular Psychiatry.

[251]  B. Fredholm,et al.  Comparative pharmacology of human adenosine receptor subtypes – characterization of stably transfected receptors in CHO cells , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[252]  R. K. Shepherd,et al.  Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. , 1997, The Journal of clinical investigation.

[253]  J. Linden,et al.  Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor. , 1997, Molecular pharmacology.

[254]  Hiroshi Kase,et al.  Adenosine A2A antagonists with potent anti-cataleptic activity , 1997 .

[255]  S. Schiffmann,et al.  Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor , 1997, Nature.

[256]  R. Lum,et al.  Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine. , 1997, Journal of medicinal chemistry.

[257]  A. IJzerman,et al.  Site-directed mutagenesis of the human A1 adenosine receptor: influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding. , 1996, Molecular pharmacology.

[258]  C. Romano,et al.  Metabotropic Glutamate Receptor 5 Is a Disulfide-linked Dimer* , 1996, The Journal of Biological Chemistry.

[259]  B. Stein,et al.  Adenosine Receptor Antagonists: Structures and Potential Therapeutic Applications , 1996, Current Pharmaceutical Design.

[260]  S. Lazareno,et al.  The affinity of adenosine for the high- and low-affinity states of the human adenosine A1 receptor. , 1996, European journal of pharmacology.

[261]  G. Firestein,et al.  Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. , 1996, Journal of immunology.

[262]  F. Ciruela,et al.  Adenosine Deaminase Interacts with A1 Adenosine Receptors in Pig Brain Cortical Membranes , 1996, Journal of neurochemistry.

[263]  J. Wess,et al.  Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. , 1996, Molecular pharmacology.

[264]  L. Belardinelli,et al.  Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology , 2012, Springer US.

[265]  F. Ciruela,et al.  Immunological identification of A1 adenosine receptors in brain cortex , 1995, Journal of neuroscience research.

[266]  K. Jacobson,et al.  "Cleavable trifunctional" approach to receptor affinity labeling: chemical regeneration of binding to A1-adenosine receptors. , 1995, Bioconjugate chemistry.

[267]  K. Jacobson,et al.  A binding site model and structure-activity relationships for the rat A3 adenosine receptor. , 1994, Molecular pharmacology.

[268]  G Burnstock,et al.  Nomenclature and Classification of Purinoceptors* , 2005 .

[269]  C. Müller,et al.  Synthesis and structure-activity relationships of deazaxanthines: analogs of potent A1- and A2-adenosine receptor antagonists. , 1994, Journal of medicinal chemistry.

[270]  J. Daly,et al.  Functional characterization of the A2b adenosine receptor in NIH 3T3 fibroblasts. , 1994, Biochemical pharmacology.

[271]  Dc Washington Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. , 1994 .

[272]  J. Linden,et al.  Molecular cloning and characterization of the human A3 adenosine receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[273]  C. Müller,et al.  Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors. , 1993, Journal of medicinal chemistry.

[274]  K. Jacobson,et al.  Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. , 1993, Journal of medicinal chemistry.

[275]  J. Daly,et al.  Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors. , 1993, Pharmacology.

[276]  S. Rivkees,et al.  RFL9 encodes an A2b-adenosine receptor. , 1992, Molecular endocrinology.

[277]  G. Stiles,et al.  Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[278]  B. Fredholm,et al.  Magnesium‐Dependent Enhancement of Endogenous Agonist Binding to A1 Adenosine Receptors: A Complicating Factor in Quantitative Autoradiography , 1992, Journal of neurochemistry.

[279]  A. IJzerman,et al.  1H-Imidazo(4,5-c)quinolin-4-amines: Novel Non-Xanthine Adenosine Antagonists. , 1991 .

[280]  M. Parmentier,et al.  The orphan receptor cDNA RDC7 encodes an A1 adenosine receptor. , 1991, The EMBO journal.

[281]  C. Müller,et al.  Caffeine analogs: structure-activity relationships at adenosine receptors. , 1991, Pharmacology.

[282]  B. Fredholm,et al.  Extracellular levels of adenosine and its metabolites in the striatum of awake rats: inhibition of uptake and metabolism. , 1991, Acta physiologica Scandinavica.

[283]  A. IJzerman,et al.  1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. , 1991, Journal of medicinal chemistry.

[284]  S Schiffmann,et al.  RDC8 codes for an adenosine A2 receptor with physiological constitutive activity. , 1990, Biochemical and biophysical research communications.

[285]  J. Fergus,et al.  Structure-activity relationships for enhancement of adenosine A1 receptor binding by 2-amino-3-benzoylthiophenes. , 1990, Molecular pharmacology.

[286]  R. Hirschhorn Adenosine deaminase deficiency. , 1987, Immunodeficiency reviews.

[287]  K. Jacobson,et al.  Species differences in structure‐activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors , 1986, FEBS letters.

[288]  A. Newby Adenosine and the concept of ‘retaliatory metabolites’ , 1984 .

[289]  R F Bruns,et al.  Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. , 1980, Canadian journal of physiology and pharmacology.